English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma

Hansen, C. R., Grimm, D., Bauer, J., Wehland, M., & Magnusson, N. E. (2017). Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma. International Journal of Molecular Sciences, 18(2): 461. doi:10.3390/ijms18020461.

Item is

Files

show Files
hide Files
:
ijms-18-00461.pdf (Publisher version), 563KB
Name:
ijms-18-00461.pdf
Description:
-
Visibility:
Public
MIME-Type / Checksum:
application/pdf / [MD5]
Technical Metadata:
Copyright Date:
-
Copyright Info:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
License:
-

Locators

show

Creators

show
hide
 Creators:
Hansen, Caroline Randrup1, Author
Grimm, Daniela1, Author
Bauer, Johann2, Author              
Wehland, Markus1, Author
Magnusson, Nils E.1, Author
Affiliations:
1external, ou_persistent22              
2Scientific Service Groups, Max Planck Institute of Biochemistry, Max Planck Society, ou_1565170              

Content

show
hide
Free keywords: TARGETED THERAPY; RETROSPECTIVE ANALYSIS; ANTITUMOR-ACTIVITY; OPEN-LABEL; PHASE-II; TRIAL; CANCER; HYPERTENSION; MANAGEMENT; EFFICACYBiochemistry & Molecular Biology; Chemistry; metastatic renal cell carcinoma; sunitinib; sorafenib; hypertension; tyrosine kinase inhibitors; vascular endothelial growth factor;
 Abstract: In recent years, targeted therapies have proven beneficial in terms of progression-free survival (PFS) and overall survival (OS) in the treatment of metastatic renal cell carcinoma (mRCC). The tyrosine kinase inhibitors (TKIs) sorafenib and sunitinib are included in international clinical guidelines as first-line and second-line therapy in mRCC. Hypertension is an adverse effect of these drugs and the degree of hypertension associates with the anti-tumour effect. Studies have compared newer targeted drugs to sorafenib and sunitinib in terms of PFS, OS, quality of life and safety profiles. Phase III studies presented promising response rates and acceptable safety profiles of axitinib and tivozanib compared to sorafenib, and a phase II study reported greater efficacy using a combination of bevacizumab and IFN- compared to sunitinib. Treatment with nintedanib exhibited a notably low prevalence of hypertension compared to sunitinib. The use of sorafenib and sunitinib are challenged by new drugs, but do not appear likely to be substituted in the near future. To clarify whether newer targeted drugs should replace sorafenib and sunitinib, more research is needed. This manuscript reviews the current utility and adverse effects of sorafenib and sunitinib and newer targeted therapies in the treatment of mRCC.

Details

show
hide
Language(s): eng - English
 Dates: 2017
 Publication Status: Published online
 Pages: 14
 Publishing info: -
 Table of Contents: -
 Rev. Type: -
 Identifiers: ISI: 000395457700228
DOI: 10.3390/ijms18020461
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: International Journal of Molecular Sciences
  Abbreviation : Int. J. Mol. Sci.
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: Basel, Switzerland : MDPI AG
Pages: - Volume / Issue: 18 (2) Sequence Number: 461 Start / End Page: - Identifier: ISSN: 1422-0067
CoNE: https://pure.mpg.de/cone/journals/resource/1422-0067